Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe parkinsonian's patients

被引:0
|
作者
Vaamonde, J [1 ]
Ibàñez, R [1 ]
Gudin, M [1 ]
Hernández, A [1 ]
机构
[1] Complejo Hosp Ciudad Real, Serv Neurol, Ciudad Real 13002, Spain
来源
NEUROLOGIA | 2003年 / 18卷 / 03期
关键词
Parkinson's disease; severity; motor complications;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Daily fluctuations of motor performance and dyskinesias in patients with Parkinson's disease (PD) treated with levodopa represent a difficult challenge to our understanding. We report 10 patients diagnosed of severe PD (Hoehn and Yahr: III-IV/V) treated with levodopa (range of dose: 750-900 mg/day) in single drug therapy since their diagnosis (mean time of levodopatherapy: 4.8 +/- 2.4 months, range: 3-6 months). All patients developed motor complications within weeks to months after initiating L-dopatherapy. Two patients received an intravenous apomorphine infusion (mean dose: 8.5 mg/day) during a mean time of 7.5 hours, but motor complications persisted during the infusion in spite of continuous dopaminergic stimulus. The degree of nigrostriatal damage (disease severity) seems to be a very important risk factor for the development of treatment-related motor complications.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 50 条
  • [21] Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia
    Rascol, O
    Sabatini, U
    Brefel, C
    Fabre, N
    Rai, S
    Senard, M
    Celsis, P
    Viallard, G
    Montastruc, JL
    Chollet, F
    BRAIN, 1998, 121 : 527 - 533
  • [22] Identifying the transcriptomic signature of L-DOPA-induced dyskinesias
    Smith, L. M.
    Duncan, E. J.
    Parr-Brownlie, L. C.
    Black, M. A.
    Dearden, P. K.
    Reynolds, J. N. J.
    MOVEMENT DISORDERS, 2013, 28 : S211 - S211
  • [23] The striatal cholinergic system in l-dopa-induced dyskinesias
    X. A. Perez
    T. Bordia
    M. Quik
    Journal of Neural Transmission, 2018, 125 : 1251 - 1262
  • [24] The striatal cholinergic system in L-dopa-induced dyskinesias
    Perez, X. A.
    Bordia, T.
    Quik, M.
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (08) : 1251 - 1262
  • [25] DEANOL AND PHYSOSTIGMINE IN TREATMENT OF L-DOPA-INDUCED DYSKINESIAS
    LINDEBOOM, SF
    LAKKE, JPWF
    ACTA NEUROLOGICA SCANDINAVICA, 1978, 58 (02): : 134 - 138
  • [26] Mechanisms and treatment of L-DOPA-induced dyskinesias - Introduction
    Danysz, W
    AMINO ACIDS, 2002, 23 (1-3) : 103 - 103
  • [27] RESPONSE OF TARDIVE AND L-DOPA-INDUCED DYSKINESIAS TO ANTIDEPRESSANTS
    ELAWAR, M
    FREEDMAN, M
    SEEMAN, P
    GOLDENBERG, L
    LITTLE, J
    SOLOMON, P
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1987, 14 (04) : 629 - 631
  • [28] Mechanisms and treatment of L-DOPA-induced dyskinesias – Introduction
    W. Danysz
    Amino Acids, 2002, 23 : 103 - 103
  • [29] Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
    Bastide, Matthieu F.
    Meissner, Wassilios G.
    Picconi, Barbara
    Fasano, Stefania
    Fernagut, Pierre-Olivier
    Feyder, Michael
    Francardo, Veronica
    Alcacer, Cristina
    Ding, Yunmin
    Brambilla, Riccardo
    Fisone, Gilberto
    Stoessl, A. Jon
    Bourdenx, Mathieu
    Engeln, Michel
    Navailles, Sylvia
    De Deurwaerdere, Philippe
    Ko, Wai Kin D.
    Simola, Nicola
    Morelli, Micaela
    Groc, Laurent
    Rodriguez, Maria-Cruz
    Gurevich, Eugenia V.
    Quik, Maryka
    Morari, Michele
    Mellone, Manuela
    Gardoni, Fabrizio
    Tronci, Elisabetta
    Guehl, Dominique
    Tison, Francois
    Crossman, Alan R.
    Kang, Un Jung
    Steece-Collier, Kathy
    Fox, Susan
    Carta, Manolo
    Cenci, M. Angela
    Bezard, Erwan
    PROGRESS IN NEUROBIOLOGY, 2015, 132 : 96 - 168
  • [30] 7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate
    Herrero, M. T.
    Yuste, J. E.
    Cuenca-Bermejo, L.
    Almela, P.
    Arenas-Betancur, L.
    De Pablos, V.
    Gonzalez-Cuello, A.
    Del Bel, E.
    Navarro-Zaragoza, J.
    Fernandez-Villalba, E.
    OPEN BIOLOGY, 2023, 13 (05)